Inactive Instrument
Incannex Healthcare Share Price Australian S.E.
Stocks
IHL
AU000000IHL8
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 58.9M 40.77M 36.21M 33.86M 30.86M 58.1M 3.93B 410M 159M 2B 153M 150M 6.42B | P/E 2027 * |
-2.72x | P/E 2028 * | -1.79x |
|---|---|---|---|---|---|
| Enterprise Value | 58.9M 40.77M 36.21M 33.86M 30.86M 58.1M 3.93B 410M 159M 2B 153M 150M 6.42B | EV / Sales 2027 * |
-
| EV / Sales 2028 * | - |
| Free-Float |
88.23% | Yield 2027 * |
-
| Yield 2028 * | - |
| 1 day | -10.87% |
| Manager | Title | Age | Since |
|---|---|---|---|
Joel Latham
CEO | Chief Executive Officer | 37 | 31/12/2015 |
Joseph Swan
DFI | Director of Finance/CFO | 35 | 28/02/2024 |
Luigi Barbato
CTO | Chief Tech/Sci/R&D Officer | 63 | 20/10/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Troy Valentine
CHM | Chairman | 52 | 31/10/2023 |
Peter Widdows
BRD | Director/Board Member | 60 | 31/10/2023 |
Joel Latham
BRD | Director/Board Member | 37 | 31/12/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -10.87% | -31.67% | - | - | 40.64M | |
| +4.16% | +3.04% | +49.37% | +94.17% | 74.46B | |
| -0.61% | +0.81% | +27.25% | +82.72% | 60.14B | |
| -2.54% | -1.65% | +4.86% | +31.72% | 48.15B | |
| -3.02% | -5.20% | +27.94% | +32.51% | 44.25B | |
| +0.31% | +3.02% | +348.95% | +643.82% | 43.99B | |
| -1.96% | -0.33% | +7.04% | +99.46% | 41.61B | |
| +3.32% | +3.49% | +10.10% | +51.23% | 29.97B | |
| -3.57% | +1.98% | +28.45% | +21.60% | 29.31B | |
| -4.86% | -10.66% | -26.27% | +330.06% | 24.93B | |
| Average | -1.96% | -0.08% | +53.08% | +154.14% | 44.09B | |
| Weighted average by Cap. | -0.45% | +0.11% | +57.74% | +145.69% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -21.35M -14.78M -13.13M -12.27M -11.19M -21.06M -1.42B -148M -57.48M -725M -55.48M -54.28M -2.33B | -30.95M -21.42M -19.03M -17.79M -16.21M -30.53M -2.06B -215M -83.33M -1.05B -80.43M -78.68M -3.37B |
| Net Debt | - | - |
Employees
12
